)
)
)
Amorphical LTD
Amorphical Ltd. develops next-generation pharmaceutical therapies based on bioactive nano-amorphous minerals, protected by 190+ global patents.
Our proprietary technology demonstrates strong preclinical and clinical results across metabolic, bone, inflammatory, and oncological diseases by enabling highly efficient absorption and targeted activity in acidic, damaged tissues.
Amorphical addresses two major biomedical challenges: poor mineral bioavailability and pathological acidosis in severe inflammatory conditions. Our clinical pipeline includes an FDA-regulated Phase 2 trial in hypoparathyroidism, alongside programs in Crohn’s disease, pancreatic cancer, and osteoporotic fractures.
The company is advancing toward full pharmaceutical-grade GMP manufacturing, strengthening strategic partnerships, and accelerating development of its mineral-based therapeutic platform.
Address
Nes ZionaIsrael
Israel
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)